Thursday 16 October, 2025
Objectives: Dolutegravir-based regimens are recommended as first-line HIV therapy in low and middle-income countries (LMIC). Rifampicin, the mainstay of tuberculosis (TB)…
Read morePoster: Drug/Disease Modelling - Infection
Semi-mechanistic pharmacodynamics modeling of aztreonam-avibactam combination to understand its antimicrobial activity against multidrug-resistant Gram-negative bacteria
Thursday 16 October, 2025
Objectives: Aztreonam-avibactam (ATM-AVI) is a promising β-lactam-β-lactamase inhibitor combination to treat serious infections caused by multi-drug resistant (MDR) pathogens including…
Read morePopulation pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations
Thursday 16 October, 2025
Introduction/Objectives: Macozinone (PBTZ-169) is a new benzothiazinone anti-tuberculosis drug candidate that selectively and irreversibly inhibits the DprE1 enzyme of Mycobacterium…
Read moreTranslational Model-Informed Selection of Tuberculosis Drug Combination Regimens for Early Clinical Development
Thursday 16 October, 2025
Objectives: There is still a gap between pre-clinical and clinical phase in tuberculosis (TB) drug development. New innovative tools are needed…
Read moreTranslational PK and PKPD modelling for the analysis of preclinical in-vitro and in-vivo studies to predict efficacious human dose of apramycin
Thursday 16 October, 2025
Objectives: Predictions of human dose for antibiotics are commonly based on 24h response in mouse infection models, ignoring the dynamics…
Read morePredictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
Thursday 16 October, 2025
Introduction: With 10 million new cases and 1.5 million deaths in 2018, tuberculosis remains a major global problem [1]. Given…
Read moreSimultaneous Assessment of Time-to-positivity and Colony-forming Unit in tuberculosis patients under high-dose rifampicin therapy
Thursday 16 October, 2025
Objectives: Colony forming unit (CFU) counting on solid agar has been used for more than three decades to measure anti-tuberculosis…
Read moreAnalysis of target-site distribution of meropenem in morbidly obese and non-obese patients using nonlinear mixed-effects modelling
Thursday 16 October, 2025
Objectives: Meropenem (MER), a broad-spectrum β-lactam antibiotic, is frequently used for the treatment of soft tissue infections, e.g. after surgery….
Read moreA target-mediated drug disposition model describing plasma and liver pharmacokinetics of JNJ-73763989 in AAV-HBV mice
Thursday 16 October, 2025
Objectives: Silencing RNA (siRNA) is a novel therapeutic modality allowing for the specific downregulation of protein expression [1]. JNJ-73763989 (subsequently…
Read moreDevelopment of an indirect response model-based meta-analysis (MBMA) framework for the description of viral antigen decline for siRNA-based anti-HBV therapies
Thursday 16 October, 2025
Objectives: Silencing/small interfering RNA (siRNA) represents a novel therapeutic modality in the field of hepatitis B virus (HBV) infection, aiming…
Read more